Atonco

Atonco is a Paris-based, private biotech pioneering a disruptive approach in targeted alpha therapy (TAT) using Astatine-211. The company holds exclusive worldwide licenses for a proprietary antibody and radiolabeling technology, positioning it in the growing field of radiopharmaceuticals. Its lead program targets non-muscle invasive bladder cancer refractory to standard treatments, aiming to provide a novel intravesical therapy that could delay or prevent radical cystectomy. As a pre-revenue, clinical-stage company, Atonco's success hinges on clinical validation of its platform and navigating the complex manufacturing and regulatory pathway for alpha-emitting therapeutics.

Proprietary platform for developing targeted alpha-immunotherapies using the radionuclide Astatine-211. The technology includes exclusive licenses for a specific antibody (anti-CAIX) and a proprietary radiolabeling method, designed to target rapidly accessible, thin tumor deposits suited to the short half-life (7.2h) and very short path length of alpha particles.

Atonco competes in the targeted alpha therapy (TAT) segment of the radiopharmaceutical market. It faces competition from companies developing other alpha-emitters (e.g., Actinium-225, Lead-212) and from large pharma (Novartis, Bayer) investing heavily in radiopharmaceuticals. Its intravesical approach for bladder cancer is relatively niche but may compete with other novel local therapies and immunotherapies in development.